PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.

@article{Xu2017PIK3CAMC,
  title={PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.},
  author={Jian-ming Xu and Yan Wang and You-liang Wang and Tao Liu and Ming Ni and Man-Sheng Li and Li Lin and Fei-jiao Ge and Chun Gong and Jun-Yan Gu and Ru Jia and He-Fei Wang and Yu-Ling Chen and Rongrui Liu and Chuan-hua Zhao and Zhao-Li Tan and Yang Xiao Jin and Yun-ping Zhu and Shuji Ogino and Zhi-Rong Qian},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2017},
  volume={23 16},
  pages={
          4602-4616
        }
}
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of the EGFR signaling pathway in conferring acquired resistance has not been extensively investigated.Experimental Design: Using circulating tumor DNA (ctDNA) from patients with mCRC and with acquired cetuximab resistance, we developed a targeted… CONTINUE READING
BETA